Anixa Biosciences, Inc. ANIX
2.58 USD -0.13 (-4.98%)
As ofNov 19, 2026, 3:01 PM EST
2.52 Day range 2.82
2.32 52-week range 5.46
- YTD
- -17.47%
- 1 year
- -40.80%
News
benzinga.com Anixa Biosciences Issued Canadian Patent Covering Its Ovarian Cancer Vaccine Technology Canadian Intellectual Property Office (CIPO) has issued Patent Number 3,005,025 covering key aspects of Anixa's ovarian cancer vaccine technology. The newly issued patent expands Anixa's international
prnewswire.com Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology New patent expands Anixa's intellectual property portfolio for its innovative ovarian cancer vaccine, complementing existing U.S. patent protection SAN JOSE, Calif., Nov. 19, 2026 /PRNewswire/ --…benzinga.com Anixa Biosciences Taps Curia To Provide Formulation Development Services For Anixa's Investigational Breast Cancer Vaccine In Preparation For Upcoming Phase 2 Clinical Trial Collaboration to support development of a stable, scalable formulation for clinical development and potential commercializationSAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.…
prnewswire.com Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization SAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.…benzinga.com Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth
